Committee delays vote on medical‑cannabis changes after members raise advertising and scope concerns

The Georgia House Health Committee discussed HB227 (LC550411), a proposal to retitle the state’s low‑THC oil program as a medical‑cannabis program, remove “severe” and “end‑stage” caveats from qualifying conditions, and clarify public awareness activities by the Georgia Access to Medical Cannabis Commission.

Sponsor Representative Dickey said the bill does not change permitted products (it does not allow smokeable flower), does not add new qualifying medical conditions, and is intended to make the program easier for patients to access and for physicians to recommend products in tested forms (oils, tinctures, patches, capsules). He said Georgia’s program currently has low patient participation compared with other states and that the bill’s name change and removal of “end‑stage” qualifiers could increase patient access.

Committee concerns: Several members questioned two features. First, some members objected to language that committee members said could be read as allowing licensees to engage in public advertising to the general public. Lawmakers urged narrowing the language and clarifying that public outreach should be limited and under the commission’s control. Second, members pressed whether the bill’s product definitions could be interpreted to permit smokeable products or edible forms attractive to children; sponsors and others said the bill was not intended to change allowable products and urged cross‑references to existing code that define legal product forms.

Amendment effort and withdrawal: Committee members debated an amendment to strike language about marketing and to limit licensees’ communication to physicians and health‑care providers. Representative Scofield asked to add lupus to the qualifying conditions; members agreed to consider that. After extended discussion and a proposal to prepare a revised substitute with clarified language about advertising, product definitions and inclusion of lupus, committee members withdrew the motion to pass and agreed that the sponsor would return with a perfected substitute for further consideration.

Next steps: The sponsor and committee chairs asked counsel to draft a substitute clarifying the advertising and public‑awareness provisions and to return with amended language. No final vote was taken at this hearing.